The updated 2026 ACC Expert Consensus Decision Pathway (ECDP) for the Management of Heart Failure With Preserved Ejection Fraction (HFpEF) reflects a significant evolution in how HFpEF is understood and treated.
The Food and Drug Administration is advising consumers not to purchase or use Kangaroo Intense Venus 3000, a product promoted for sexual enhancement on various websites, including https://usroyalhoney.com, and possibly in some retail stores.
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): June 2025 to June 2026.
by Gemma C. Sharp, Deborah A. Lawlor, Kayleigh E. Easey, Sampurna Kundu, Ahmed Elhakeem, Edward Hone, Rosemary R. C. McEachan, Maria C. Magnus, Alexandra Havdahl, Caroline L. Relton Background The Developmental Origins of Health and Disease (DOHaD) hypothesis suggests that early life environmental exposures, especially during pregnancy, can impact long-term health. Research has largely relied on correlational evidence and has focussed on maternal factors, with less attention given to paternal, postnatal, and broader social determinants. This focus could complicate efforts to determine the most…
This 2-day workshop will address some of the key product development and regulatory assessment considerations for generic glucagon-like peptide-1 (GLP-1) agonist products.
Hospitals that see improved long-term results in behavioral health patients will be those that prioritize metrics aligned with their care pathways. The post Rethinking How Hospitals Measure Behavioral Health Success appeared first on MedCity News .
Groundbreaking new therapies have exciting potential to treat and cure diseases while minimizing burden on patients; however, they create major clinical, operational and financial implications that must be planned for years in advance. The post Four Ways Health Systems Should Plan for the Next Wave of Breakthrough Therapies appeared first on MedCity News .
Scancell and Neuphoria have made their union official via a reverse merger that will result in a Nasdaq listing for Scancell and a resolution for Neuphoria’s shareholders after the biotech ended its social anxiety program last year.
Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged release 20mg, 30mg and 40mg chewable tablets.
A year after the Environmental Protection Agency stripped grant money from dozens of communities nationwide during Trump’s DEI crackdown, a small Georgia city is struggling to address environmental health concerns.
In a church in rural Missouri, mourners lined up to say goodbye to Lloyd Gilmore, a 44-year-old Black father who died in police custody last month. His death sparked protests in a city with a long history of racial violence, even as the national conversation about police brutality has waned. Six years after worldwide calls for change, what’s happened to the movement?
The number of infections of Shiga-toxin producing Escherichia coli (STEC) reported in England and Wales for 2019 and 2020, and England only from 2021 onwards.
Eli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak weight loss fell short of previous trials while failing to prove the drug reduces cardiovascular risk.